Firm Characteristics and the Speed of FDA Approval

Mary Olson

Journal of Economics & Management Strategy, 1997, vol. 6, issue 1, 377-401

Abstract: This paper empirically examines the effect of firm‐specific characteristics on the length of time required by the Food and Drug Administration (FDA) to review and approve new‐drug applications between 1990 and 1992. The approach treats regulatory decisions as endogenous and explains the variation in regulatory behavior as a function of differences that exist between firms and drugs. Results show that, controlling for drug‐specific characteristics, regulators respond to firm‐specific characteristics when evaluating new drug applications. For instance, firms that are less diversified and more R&D‐inten‐sive receive shorter review times for their new‐drug applications than more diversified and less R&D‐intensive firms. The reason is that most firm characteristics signal information to reviewers about either firm reputation or application quality. This information reduces reviewers' uncertainty about approving a dangerous or ineffective drug and leads to faster review times. The results suggest that regulators respond to the heterogeneities among firms in the pharmaceutical market in systematic ways.

Date: 1997
References: View references in EconPapers View complete reference list from CitEc
Citations: View citations in EconPapers (18)

Downloads: (external link)
https://doi.org/10.1111/j.1430-9134.1997.00377.x

Related works:
This item may be available elsewhere in EconPapers: Search for items with the same title.

Export reference: BibTeX RIS (EndNote, ProCite, RefMan) HTML/Text

Persistent link: https://EconPapers.repec.org/RePEc:bla:jemstr:v:6:y:1997:i:1:p:377-401

Ordering information: This journal article can be ordered from
http://www.blackwell ... ref=1058-6407&site=1

Access Statistics for this article

More articles in Journal of Economics & Management Strategy from Wiley Blackwell
Bibliographic data for series maintained by Wiley Content Delivery ().